With over 1.35 billion people, healthcare in China is already a huge, and growing, market..
On 19 September 2012, SFDA released the Rules on Imposing Administrative Penalties for Drugs and Medical Equipment.
The new code has further refined and defined the relevant requirements and standards for medical promotion.
To address China's aging population issue and to improve access in rural areas, healthcare reform has become a priority.
On 22 January 2013, the PRC Ministry of Health issued the revised Good Supply Practice for Pharmaceutical Distribution, which will take effect 1 June 2013.
The PRC Ministry of Health has proposed to revise the current Measures for Inspection of Medical Advertisement.
Consultations during recent NPC and CPPCC sessions regarding food safety aimed to further promote institutional reform.
On 22 January 2013, the PRC’s National Development and Reform Commission issued guidance on accelerating consolidation within the pharmaceutical sector.
A discussion on the investigations relating to the ever-increasing online sale of pharmaceuticals in China.
The Fall/Winter 2012 issue of our China Life Sciences Newsletter, a periodic update on key developments, companies, and people in the dynamic China life sciences industry.
On 8 January 2013, SFDA released a report concerning the results of its continuing investigations into online pharmaceutical trading activities conducted pursuant to their notice issued by them on 24 February 2012.
The Chinese State Food and Drug Administration announced a plan for regulatory reform and is soliciting public comments through January 15, 2013.
China has become the world’s largest market for generic pharmaceuticals. Generics account for more than 90% of China’s total pharmaceutical market.
The State Food and Drug Administration recently announced a set of technical guidelines for switching prescription drugs to over-the-counter drugs.
Chinese State Food and Drug Administration ("SFDA") issued a draft Work Plan for Quality Consistency Evaluation for Generic Drugs ("Work Plan") on November 22 for public comments through December 6.
The government, on May 16, 2013, notified new norms that will bring down prices of essential medicines, increase the number of drugs under price control, and alter the way the government regulates prices in the 72,000 crore domestic market.
The government may give drug companies just 45 days to comply with the upcoming pricing regime that promises cheaper essential medicines, making it mandatory for companies to conform to revised rates irrespective of the date of manufacture.
The officials at the Health Ministry have recently said that they are planning to bring in a clear provision in the law to promote generic drugs.